BioWorld MedTech

Sep. 22, 2016

Analysts sift through Abbott unit sale to find read-through for contested Alere deal

Abbott Laboratories' divestiture of its optics business could indicate that the company is ready to bite the figurative Alere Inc. bullet and move forward with that $5.8 billion acquisition – but not necessarily. Read More

Califf says combo products 'on my mind,' along with cross-center coordination

Spirox's Latera absorbable nasal implant technology demonstrates significant quality of life improvement

Weak clinical trial data in China leads to a rush of device withdrawals

Financings

Appointments and advancements

Product briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for April 4, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 4, 2025.

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

3D rendering of glucagon-like peptide 1 (GLP-1)

ADPD 2025: Unlocking GLP-1's potential in neurodegeneration

BioWorld

At the recently launched Alzheimer’s & Parkinson’s Diseases Conference held in Vienna, Lotte Bjerre Knudsen from Novo Nordisk A/S, who has extensive experience in...

Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.

Checkpoint inhibitor journey traces Chinese firms’ path to global revenue

BioWorld

Chinese pharmaceutical companies are making significant inroads into the global oncology market, particularly with the development and approval of immune...